Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location
Highlights
This retrospective cohort study of 133 patients with recurrent endometrial (EC) and cervical cancer (CC) reveals that immunotherapy response rates and survival outcomes do not significantly differ based on recurrence location relative to prior radiation fields. Complete response rates ranged from 10% to 44.4% across groups, suggesting that prior radiotherapy should not preclude immunotherapy consideration in these patient populations.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.